AWD 12187

Drug Profile

AWD 12187

Latest Information Update: 23 Aug 2007

Price : $50

At a glance

  • Originator elbion
  • Class
  • Mechanism of Action Phosphodiesterase VII inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hypersensitivity

Most Recent Events

  • 08 Dec 2003 No development reported - Preclinical for Allergy in Germany (unspecified route)
  • 06 Jun 2000 Preclinical development for Allergy in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top